RAS-ing the bar in the treatment of KRAS-mutant cholangiocarcinoma.

Abstract excerpt

Despite progress in elucidating the molecular landscape and actionable vulnerabilities of cholangiocarcinoma, clinical outcomes for patients with advanced disease remain dismal. In this issue of Cancer Cell, Entrialgo-Cadierno et al. raise the bar for the ∼20%-25% of patients with oncogenic KRAS mutations by unlocking the therapeutic potential of direct RAS-GTP inhibition.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bile Duct Neoplasms
• Share to Bile Ducts, Intrahepatic
• Share to Cholangiocarcinoma